[
    [
        {
            "time": "",
            "orginal_text": "新生物创新系列研究之二：CD20靶点单抗 针对淋巴瘤的大品种",
            "features": {
                "keywords": [
                    "CD20靶点",
                    "单抗",
                    "淋巴瘤",
                    "大品种"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "新生物创新系列研究之二：CD20靶点单抗 针对淋巴瘤的大品种",
            "scores": {
                "News_content": "新生物创新系列研究之二：CD20靶点单抗 针对淋巴瘤的大品种",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "医药行业17年报及18年一季报小结",
            "features": {
                "keywords": [
                    "年报",
                    "一季报",
                    "医药行业"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药行业17年报及18年一季报小结",
            "scores": {
                "News_content": "医药行业17年报及18年一季报小结",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业：全行业景气度回升继续推荐优质成长股",
            "features": {
                "keywords": [
                    "医药生物",
                    "景气度",
                    "优质成长股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药生物行业：全行业景气度回升继续推荐优质成长股",
            "scores": {
                "News_content": "医药生物行业：全行业景气度回升继续推荐优质成长股",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "医药板块概念股复星医药：贝伐珠单抗启动III期临床",
            "features": {
                "keywords": [
                    "医药板块",
                    "复星医药",
                    "贝伐珠单抗",
                    "III期临床"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "医药板块概念股复星医药：贝伐珠单抗启动III期临床",
            "scores": {
                "News_content": "医药板块概念股复星医药：贝伐珠单抗启动III期临床",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "申万宏源：医药生物全行业景气度回升",
            "features": {
                "keywords": [
                    "申万宏源",
                    "医药生物",
                    "景气度"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "申万宏源：医药生物全行业景气度回升",
            "scores": {
                "News_content": "申万宏源：医药生物全行业景气度回升",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "本周A股或有一场激战 10只股被机构集中推荐(附股)",
            "features": {
                "keywords": [
                    "A股",
                    "机构推荐",
                    "股票"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "本周A股或有一场激战 10只股被机构集中推荐(附股)",
            "scores": {
                "News_content": "本周A股或有一场激战 10只股被机构集中推荐(附股)",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "社保和公募纷纷扎堆医药板块 六股有望率先发力",
            "features": {
                "keywords": [
                    "社保",
                    "公募",
                    "医药板块",
                    "六股"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "社保和公募纷纷扎堆医药板块 六股有望率先发力",
            "scores": {
                "News_content": "社保和公募纷纷扎堆医药板块 六股有望率先发力",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "“代理+创新”助疫苗业繁荣 近2亿大单抢筹6只潜力股",
            "features": {
                "keywords": [
                    "代理",
                    "创新",
                    "疫苗业",
                    "大单",
                    "潜力股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "“代理+创新”助疫苗业繁荣 近2亿大单抢筹6只潜力股",
            "scores": {
                "News_content": "“代理+创新”助疫苗业繁荣 近2亿大单抢筹6只潜力股",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]